

# James W Murrough

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/615471/james-w-murrough-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137  
papers

10,138  
citations

49  
h-index

100  
g-index

162  
ext. papers

12,633  
ext. citations

7.3  
avg, IF

6.36  
L-index

#	Paper	IF	Citations
137	Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 1134-42	11.9	725
136	Neurobiology of resilience. <i>Nature Neuroscience</i> , <b>2012</b> , 15, 1475-84	25.5	715
135	Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. <i>Biological Psychiatry</i> , <b>2013</b> , 74, 250-6	7.9	498
134	Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. <i>Biological Psychiatry</i> , <b>2010</b> , 67, 139-45	7.9	480
133	Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 16136-41	11.5	424
132	Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. <i>American Journal of Psychiatry</i> , <b>2006</b> , 163, 1784-90	11.9	374
131	Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. <i>JAMA Psychiatry</i> , <b>2014</b> , 71, 681-8	14.5	337
130	The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. <i>American Journal of Psychiatry</i> , <b>2018</b> , 175, 150-158	11.9	311
129	A randomized controlled trial of intranasal ketamine in major depressive disorder. <i>Biological Psychiatry</i> , <b>2014</b> , 76, 970-6	7.9	277
128	A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , <b>2016</b> , 173, 816-26	11.9	276
127	Relation between resting amygdalar activity and cardiovascular events: a longitudinal and cohort study. <i>Lancet, The</i> , <b>2017</b> , 389, 834-845	40	269
126	Targeting glutamate signalling in depression: progress and prospects. <i>Nature Reviews Drug Discovery</i> , <b>2017</b> , 16, 472-486	64.1	234
125	Cognitive dysfunction in depression: neurocircuitry and new therapeutic strategies. <i>Neurobiology of Learning and Memory</i> , <b>2011</b> , 96, 553-63	3.1	222
124	Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. <i>Depression and Anxiety</i> , <b>2014</b> , 31, 335-43	8.4	220
123	Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. <i>International Journal of Neuropsychopharmacology</i> , <b>2010</b> , 13, 71-82	5.8	197
122	Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. <i>Psychological Medicine</i> , <b>2015</b> , 45, 3571-80	6.9	181
121	Ketamine Treatment and Global Brain Connectivity in Major Depression. <i>Neuropsychopharmacology</i> , <b>2017</b> , 42, 1210-1219	8.7	179

120	A functional magnetic resonance imaging study of deliberate emotion regulation in resilience and posttraumatic stress disorder. <i>Biological Psychiatry</i> , <b>2009</b> , 66, 656-64	7.9	178
119	Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. <i>Biological Psychiatry</i> , <b>2009</b> , 65, 792-800	7.9	177
118	Ketamine for treatment-resistant unipolar depression: current evidence. <i>CNS Drugs</i> , <b>2012</b> , 26, 189-204	6.7	170
117	ECT in treatment-resistant depression. <i>American Journal of Psychiatry</i> , <b>2012</b> , 169, 1238-44	11.9	154
116	Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. <i>International Journal of Neuropsychopharmacology</i> , <b>2014</b> , 17, 331-6	5.8	149
115	Ketamine safety and tolerability in clinical trials for treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , <b>2015</b> , 76, 247-52	4.6	136
114	Ketamine as a novel antidepressant: from synapse to behavior. <i>Clinical Pharmacology and Therapeutics</i> , <b>2012</b> , 91, 303-9	6.1	129
113	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 1592-1603	15.1	125
112	Attention bias variability and symptoms of posttraumatic stress disorder. <i>Journal of Traumatic Stress</i> , <b>2014</b> , 27, 232-239	3.8	113
111	Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. <i>NMR in Biomedicine</i> , <b>2012</b> , 25, 1073-87	4.4	106
110	Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. <i>Translational Psychiatry</i> , <b>2017</b> , 7, e1065	8.6	102
109	Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. <i>Psychopharmacology</i> , <b>2011</b> , 213, 547-53	4.7	96
108	Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. <i>Neuropsychopharmacology</i> , <b>2015</b> , 40, 1084-90	8.7	89
107	Reduced global functional connectivity of the medial prefrontal cortex in major depressive disorder. <i>Human Brain Mapping</i> , <b>2016</b> , 37, 3214-23	5.9	87
106	Neurobiology of Resilience: Interface Between Mind and Body. <i>Biological Psychiatry</i> , <b>2019</b> , 86, 410-420	7.9	85
105	Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 1827-1845	15.1	79
104	KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. <i>Nature Communications</i> , <b>2016</b> , 7, 11671	17.4	74
103	Emerging drugs for the treatment of anxiety. <i>Expert Opinion on Emerging Drugs</i> , <b>2015</b> , 20, 393-406	3.7	73

102	Ketamine for treatment-resistant depression: recent developments and clinical applications. <i>Evidence-Based Mental Health</i> , <b>2016</b> , 19, 35-8	11.1	73
101	Acetyl-L-carnitine deficiency in patients with major depressive disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, 8627-8632	11.5	68
100	Novel glutamatergic drugs for the treatment of mood disorders. <i>Neuropsychiatric Disease and Treatment</i> , <b>2013</b> , 9, 1101-12	3.1	68
99	Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 383-399	11.9	67
98	Reduced amygdala serotonin transporter binding in posttraumatic stress disorder. <i>Biological Psychiatry</i> , <b>2011</b> , 70, 1033-8	7.9	66
97	Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. <i>Translational Psychiatry</i> , <b>2015</b> , 5, e509	8.6	65
96	A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating Epioid antagonism as a treatment for anhedonia. <i>Nature Medicine</i> , <b>2020</b> , 26, 760-768	50.5	63
95	The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. <i>Archives of General Psychiatry</i> , <b>2011</b> , 68, 892-900		61
94	Ketamine for suicidal ideation in adults with psychiatric disorders: A systematic review and meta-analysis of treatment trials. <i>Australian and New Zealand Journal of Psychiatry</i> , <b>2020</b> , 54, 29-45	2.6	59
93	Neurocognitive effects of ketamine in treatment-resistant major depression: association with antidepressant response. <i>Psychopharmacology</i> , <b>2013</b> , 231, 481	4.7	57
92	Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. <i>NMR in Biomedicine</i> , <b>2010</b> , 23, 643-50	4.4	57
91	The promise of ketamine for treatment-resistant depression: current evidence and future directions. <i>Annals of the New York Academy of Sciences</i> , <b>2015</b> , 1345, 47-58	6.5	56
90	Is there anything really novel on the antidepressant horizon?. <i>Current Psychiatry Reports</i> , <b>2012</b> , 14, 643-99.1		52
89	Shared Neural Phenotypes for Mood and Anxiety Disorders: A Meta-analysis of 226 Task-Related Functional Imaging Studies. <i>JAMA Psychiatry</i> , <b>2020</b> , 77, 172-179	14.5	50
88	Cerebellar morphology and the effects of stimulant medications in youths with attention deficit-hyperactivity disorder. <i>Neuropsychopharmacology</i> , <b>2014</b> , 39, 718-26	8.7	45
87	Neuropeptide Y, resilience, and PTSD therapeutics. <i>Neuroscience Letters</i> , <b>2017</b> , 649, 164-169	3.3	41
86	Cognitive-emotional training as an intervention for major depressive disorder. <i>Depression and Anxiety</i> , <b>2014</b> , 31, 699-706	8.4	41
85	A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2018</b> , 21, 3-11	5.8	38

84	Positron emission tomography shows elevated cannabinoid CB1 receptor binding in men with alcohol dependence. <i>Alcoholism: Clinical and Experimental Research</i> , <b>2012</b> , 36, 2104-9	3.7	38
83	A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. <i>European Neuropsychopharmacology</i> , <b>2011</b> , 21, 221-9	1.2	38
82	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Frontiers in Psychiatry</i> , <b>2020</b> , 11, 595584	5	37
81	A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 193-202	11.9	37
80	Pharmacological Treatments for Patients with Treatment-Resistant Depression. <i>Pharmaceuticals</i> , <b>2020</b> , 13,	5.2	36
79	Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 975-981	8.7	36
78	Neural correlates of interoception: Effects of interoceptive focus and relationship to dimensional measures of body awareness. <i>Human Brain Mapping</i> , <b>2017</b> , 38, 6068-6082	5.9	36
77	In vivo (1)H MRS study of potential associations between glutathione, oxidative stress and anhedonia in major depressive disorder. <i>Neuroscience Letters</i> , <b>2014</b> , 569, 74-9	3.3	35
76	The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. <i>Nature Reviews Drug Discovery</i> , <b>2018</b> , 18, 82-84	64.1	33
75	A case of sustained remission following an acute course of ketamine in treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 414-5	4.6	31
74	Dextromethorphan/quinidine pharmacotherapy in patients with treatment resistant depression: A proof of concept clinical trial. <i>Journal of Affective Disorders</i> , <b>2017</b> , 218, 277-283	6.6	30
73	Neural correlates of rumination in major depressive disorder: A brain network analysis. <i>NeuroImage: Clinical</i> , <b>2020</b> , 25, 102142	5.3	30
72	A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo. <i>Journal of Affective Disorders</i> , <b>2018</b> , 230, 56-64	6.6	28
71	Cortical abnormalities and association with symptom dimensions across the depressive spectrum. <i>Journal of Affective Disorders</i> , <b>2016</b> , 190, 529-536	6.6	27
70	Psychological Impact of the COVID-19 Pandemic on Frontline Health Care Workers During the Pandemic Surge in New York City. <i>Chronic Stress</i> , <b>2021</b> , 5, 2470547020977891	3	27
69	Cracking the moody brain: lifting the mood with ketamine. <i>Nature Medicine</i> , <b>2010</b> , 16, 1384-5	50.5	26
68	Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorder. <i>Molecular Psychiatry</i> , <b>2020</b> , 25, 1323-1333	15.1	26
67	Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. <i>Journal of Clinical Psychiatry</i> , <b>2020</b> , 81,	4.6	25

66	The role of the locus coeruleus in the generation of pathological anxiety. <i>Brain and Neuroscience Advances</i> , <b>2020</b> , 4, 2398212820930321	4	24
65	Ultra-high field MRI reveals mood-related circuit disturbances in depression: a comparison between 3-Tesla and 7-Tesla. <i>Translational Psychiatry</i> , <b>2019</b> , 9, 94	8.6	24
64	Insulin receptor substrate in brain-enriched exosomes in subjects with major depression: on the path of creation of biosignatures of central insulin resistance. <i>Molecular Psychiatry</i> , <b>2021</b> , 26, 5140-5149	15.1	23
63	Selective kappa-opioid antagonism ameliorates anhedonic behavior: evidence from the Fast-fail Trial in Mood and Anxiety Spectrum Disorders (FAST-MAS). <i>Neuropsychopharmacology</i> , <b>2020</b> , 45, 1656-1663	8.7	23
62	Lithium continuation therapy following ketamine in patients with treatment resistant unipolar depression: a randomized controlled trial. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 1812-1819	8.7	21
61	Determinants and Predictive Value of Clinician Assessment of Short-Term Suicide Risk. <i>Suicide and Life-Threatening Behavior</i> , <b>2019</b> , 49, 614-626	3.9	21
60	Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 1233-1238	8.7	20
59	Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the prefrontal cortex. <i>World Journal of Biological Psychiatry</i> , <b>2020</b> , 21, 696-710	3.8	20
58	Moral distress in frontline healthcare workers in the initial epicenter of the COVID-19 pandemic in the United States: Relationship to PTSD symptoms, burnout, and psychosocial functioning. <i>Depression and Anxiety</i> , <b>2021</b> , 38, 1007-1017	8.4	20
57	The serotonin transporter and emotionality: risk, resilience, and new therapeutic opportunities. <i>Biological Psychiatry</i> , <b>2011</b> , 69, 510-2	7.9	19
56	Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression. <i>Translational Psychiatry</i> , <b>2018</b> , 8, 280	8.6	18
55	ELECTroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol. <i>Contemporary Clinical Trials</i> , <b>2019</b> , 77, 19-26	2.3	16
54	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). <i>Brain Stimulation</i> , <b>2018</b> , 11, 75-84	5.1	14
53	Ketamine for Depression: An Update. <i>Biological Psychiatry</i> , <b>2016</b> , 80, 416-418	7.9	14
52	The serotonin 1B receptor: a new target for depression therapeutics?. <i>Biological Psychiatry</i> , <b>2011</b> , 69, 714-5	7.9	13
51	Development of the Ketamine Side Effect Tool (KSET). <i>Journal of Affective Disorders</i> , <b>2020</b> , 266, 615-620	6.6	12
50	Effects of chronic physical disease and systemic inflammation on suicide risk in patients with depression: a hospital-based case-control study. <i>Psychological Medicine</i> , <b>2020</b> , 50, 29-37	6.9	12
49	High-dose ondansetron reduces activation of interoceptive and sensorimotor brain regions. <i>Neuropsychopharmacology</i> , <b>2019</b> , 44, 390-398	8.7	11

48	Current Status of Ketamine and Related Therapies for Mood and Anxiety Disorders. <i>Current Behavioral Neuroscience Reports</i> , <b>2015</b> , 2, 216-225	1.7	11
47	The Neurobiology of Resilience: Complexity and Hope. <i>Biological Psychiatry</i> , <b>2019</b> , 86, 406-409	7.9	10
46	Hippocampal subfield-specific connectivity findings in major depressive disorder: A 7 Tesla diffusion MRI study. <i>Journal of Psychiatric Research</i> , <b>2019</b> , 111, 186-192	5.2	10
45	Prazosin during threat discrimination boosts memory of the safe stimulus. <i>Learning and Memory</i> , <b>2017</b> , 24, 597-601	2.8	10
44	Corticotropin-Releasing Factor Type 1 Receptor Antagonists for Stress-Related Disorders: Time to Call It Quits?. <i>Biological Psychiatry</i> , <b>2017</b> , 82, 858-860	7.9	9
43	Advances in Psychopharmacology for Anxiety Disorders. <i>Focus (American Psychiatric Publishing)</i> , <b>2014</b> , 12, 152-162	1.1	8
42	Depletion of brain norepinephrine does not reduce spontaneous ambulatory activity of rats in the home cage. <i>Brain Research</i> , <b>2000</b> , 883, 125-30	3.7	8
41	A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , <b>2020</b> , 23, 783-790	5.8	7
40	Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , <b>2021</b> , 24, 383-391	5.8	7
39	Sub-millimeter variation in human locus coeruleus is associated with dimensional measures of psychopathology: An in vivo ultra-high field 7-Tesla MRI study. <i>NeuroImage: Clinical</i> , <b>2020</b> , 25, 102148	5.3	6
38	Analysis of Clinical Trial Exit Interview Data in Patients with Treatment-Resistant Depression. <i>Patient</i> , <b>2019</b> , 12, 527-537	3.7	6
37	Reply to: Dose- and Exposure-Response to Ketamine in Depression. <i>Biological Psychiatry</i> , <b>2011</b> , 70, e11-e13	1.3	6
36	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , <b>2021</b> , 178, 437-446	11.9	6
35	A randomized, controlled pilot trial of the Emotional Faces Memory Task: a digital therapeutic for depression. <i>Npj Digital Medicine</i> , <b>2018</b> , 1,	15.7	5
34	Ketamine for posttraumatic stress disorder--reply. <i>JAMA Psychiatry</i> , <b>2015</b> , 72, 95-6	14.5	4
33	A prospective cohort study of the psychological consequences of the COVID-19 pandemic on frontline healthcare workers in New York City.. <i>International Archives of Occupational and Environmental Health</i> , <b>2022</b> , 1	3.2	4
32	Transdiagnostic Psychiatric Symptoms, Burnout, and Functioning in Frontline Health Care Workers Responding to the COVID-19 Pandemic: A Symptomics Analysis. <i>Journal of Clinical Psychiatry</i> , <b>2021</b> , 82,	4.6	4
31	Vortioxetine Versus Placebo for Major Depressive Disorder: A Comprehensive Analysis of the Clinical Trial Dataset. <i>Journal of Clinical Psychiatry</i> , <b>2021</b> , 82,	4.6	4



30	Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence. <i>Advances in Pharmacology</i> , <b>2020</b> , 89, 163-194	5.7	3
29	Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 565	8.6	3
28	The Implications of Neurocognitive Deficits in Posttraumatic Stress Disorder. <i>Psychiatric Annals</i> , <b>2011</b> , 41, 408-412	0.5	3
27	Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. <i>Neuropsychopharmacology</i> , <b>2021</b> , 46, 2266-2277	8.7	3
26	Factors Associated With Longitudinal Psychological and Physiological Stress in Health Care Workers During the COVID-19 Pandemic: Observational Study Using Apple Watch Data. <i>Journal of Medical Internet Research</i> , <b>2021</b> , 23, e31295	7.6	3
25	Dissociating self-generated volition from externally-generated motivation. <i>PLoS ONE</i> , <b>2020</b> , 15, e0232947	4.7	2
24	Protein Biomarkers in Major Depressive Disorder: An Update. <i>Advances in Experimental Medicine and Biology</i> , <b>2019</b> , 1140, 585-600	3.6	2
23	"Does Ketamine Have Rapid Anti-Suicidal Ideation Effects?". <i>Current Treatment Options in Psychiatry</i> , <b>2015</b> , 2, 383-393	3.1	2
22	Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. <i>Focus (American Psychiatric Publishing)</i> , <b>2021</b> , 19, 222-242	1.1	2
21	Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. <i>Depression and Anxiety</i> , <b>2021</b> , 38, 1108-1119	8.4	2
20	Beyond the neuron: Role of non-neuronal cells in stress disorders.. <i>Neuron</i> , <b>2022</b> ,	13.9	2
19	Glutamate NMDA receptor modulators for the treatment of depression: trials and tribulations. <i>Psychopharmacology</i> , <b>2015</b> , 232, 1497-9	4.7	1
18	Current Treatments for Anxiety and Obsessive-Compulsive Disorders. <i>Current Treatment Options in Psychiatry</i> , <b>2014</b> , 1, 248-262	3.1	1
17	Overcoming Antidepressant Treatment Resistance: Focus on Glutamate. <i>Modern Problems of Pharmacopsychiatry</i> , <b>2010</b> , 89-100		1
16	Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression.. <i>Translational Psychiatry</i> , <b>2022</b> , 12, 12	8.6	1
15	Intrasubject functional connectivity related to self-generated thoughts. <i>Brain and Behavior</i> , <b>2021</b> , 11, e01860	3.4	1
14	Ultra-high field MRI reveals mood-related circuit disturbances in depression: A comparison between 3-Tesla and 7-Tesla		1
13	Ketamine Mechanism of Rapid Antidepressant Activity: Evidence Gleaned from Clinical Studies <b>2016</b> , 99-121		1



12	Role of nitric oxide signaling in the antidepressant mechanism of action of ketamine: A randomized controlled trial. <i>Journal of Psychopharmacology</i> , <b>2021</b> , 35, 124-127	4.6	1
11	The Potential of KCNQ Potassium Channel Openers as Novel Antidepressants.. <i>CNS Drugs</i> , <b>2022</b> , 36, 2076.7		1
10	Initial Evidence for Brain Plasticity Following a Digital Therapeutic Intervention for Depression. <i>Chronic Stress</i> , <b>2019</b> , 3, 2470547019877880	3	0
9	Psychopharmacology and Experimental Therapeutics for Bipolar Depression. <i>Focus (American Psychiatric Publishing)</i> , <b>2019</b> , 17, 232-237	1.1	0
8	Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date. <i>Drug Design, Development and Therapy</i> , <b>2021</b> , 15, 151-157	4.4	0
7	Chemical, Manufacturing, and Standardization Controls of Grape Polyphenol Dietary Supplements in Support of a Clinical Study: Mass Uniformity, Polyphenol Dosage, and Profiles.. <i>Frontiers in Nutrition</i> , <b>2021</b> , 8, 780226	6.2	0
6	Altered hippocampus and amygdala subregion connectome hierarchy in major depressive disorder.. <i>Translational Psychiatry</i> , <b>2022</b> , 12, 209	8.6	0
5	CHAPTER 9:Neurocircuitry of Anxiety Disorders: Focus on Panic Disorder and Post-traumatic Stress Disorder. <i>RSC Drug Discovery Series</i> , <b>2012</b> , 226-257	0.6	
4	Depressive Disorders <b>2016</b> , 57-73		
3	Functional Neuroanatomy <b>2016</b> , 12-17		
2	Clinical Use of Laboratory Tests, Brain Imaging, and Biomarkers <b>2016</b> , 28-39		
1	Pharmacological Treatments for Anhedonia.. <i>Current Topics in Behavioral Neurosciences</i> , <b>2022</b> , 1	3.4	